EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay

Michael J Wilkinson iD, Michael D Shapiro iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2024-12 · 44 (12) · 2396-2406

DOI: 10.1161/atvbaha.124.319983 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024-12. Verfasst von Michael J Wilkinson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, University of California San Diego, La Jolla (M.J.W.). Hauptthemen laut MEDLINE: Dyslipidemias, Cardiovascular Diseases, Heart Disease Risk Factors, Inflammation. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Individuals with autoimmune inflammatory diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and psoriasis, are at increased risk for cardiovascular disease. While these diseases share common features of systemic inflammation, the impact of individual autoimmune inflammatory conditions on circulating lipids and lipoproteins varies by specific disease, disease activity, and the immune-suppressing medications used to treat these conditions. A common feature observed in many autoimmune inflammatory diseases is the development of a proatherogenic dyslipidemic state, characterized by dysfunctional HDLs (high-density lipoproteins) and increased oxidation of LDLs (low-density lipoproteins). Various disease-modifying antirheumatic drugs also have complex and variable effects on lipids, and it is critical to take this into consideration when evaluating lipid-related risk in individuals with immune-mediated inflammatory conditions. This review aims to critically evaluate the current understanding of the relationship between immune-mediated inflammatory diseases and dyslipidemia, the underlying mechanisms contributing to atherogenesis, and the impact of various pharmacotherapies on lipid profiles and cardiovascular risk. We also discuss the role of lipid-lowering therapies, particularly statins, in managing residual risk in this high-risk population and explore the potential of emerging therapies with complementary anti-inflammatory and lipid-lowering effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyslipidemiasCardiovascular DiseasesHeart Disease Risk FactorsInflammationHumansRisk AssessmentAnimalsAutoimmune DiseasesAnti-Inflammatory AgentsHypolipidemic AgentsHydroxymethylglutaryl-CoA Reductase Inhibitors

Stichwörter der Autor:innen

atherosclerosisautoimmune diseasescardiovascular diseasesdyslipidemiasinflammation

Substanzen

Anti-Inflammatory AgentsHypolipidemic AgentsHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Department of Medicine, University of California San Diego, La Jolla (M.J.W.).
  • Section on Cardiovascular Medicine, Center for Prevention of Cardiovascular Disease, Wake Forest University School of Medicine, Winston-Salem, NC (M.D.S.).

ORCID-Profile: Michael J Wilkinson, Michael D Shapiro

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Wilkinson, M. J., & Shapiro, M. D. (2024). Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay. Arteriosclerosis, Thrombosis, and Vascular Biology, 44(12), 2396-2406. https://doi.org/10.1161/atvbaha.124.319983

Vancouver

Wilkinson MJ, Shapiro MD. Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;44(12):2396-2406. doi:10.1161/atvbaha.124.319983

BibTeX
@article{Wilkinson2024,
  author = {Wilkinson, Michael J and Shapiro, Michael D},
  title = {Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2024},
  volume = {44},
  number = {12},
  pages = {2396--2406},
  doi = {10.1161/atvbaha.124.319983}
}
Kostenlos starten →